Cobalamin, Microbiota and Epigenetics

  • Joan JoryEmail author
Living reference work entry


Functional cobalamin (B12) status and assessment are inextricably intertwined with the human microbiome. Small bowel bacterial overgrowth can both cause and result from gastritis and alter dietary cobalamin absorption. Some bacterial species may produce human-inaccessible cobalamin corrinoids and may create competition for human-accessible cobalamin. Increased human-inaccessible corrinoids from bacterial production may raise the total corrinoid level assessed by the serum total cobalamin, limiting diagnostic utility and masking a deficiency of human-accessible cobalamin. Anaerobic bacteria may reverse the propionic to succinic acid pathway, converting methylmalonic acid back to propionic acid to release CO2; this could raise propionic acid and lower methylmalonic acid levels, limiting its diagnostic utility. Cobalamin deficiency limits enzymatic conversion of homocysteine to methionine and increases homocysteine levels. Increased homocysteine can be reduced by diversion into the transsulfuration pathway, limiting the diagnostic power of this metabolite. Finally, in the delicate balance between folate and cobalamin which regulates DNA synthesis, excess synthetic folate from public health policies can combine with bacterial folate production to mask the macrocytic anemia of cobalamin deficiency.

Small bowel bacterial overgrowth can increase propionic acid production and reduce cobalamin bioavailability. Both propionic acid administration and cobalamin deficiency can alter brain fatty acid levels and brain function and cause autistic symptomology. Essential fatty acid ratios can modify gut bacterial species which can, in turn, modify fatty acid composition and inflammation. Omega-3 supplementation can reverse many of the symptoms of propionic acid neurotoxicity. Cobalamin supplementation can raise omega-3 fatty acid levels in the brain and can improve autism symptomology. Therefore, there are strong epigenetic interrelationships among cobalamin and its enzymatic activity, propionic acid, essential fatty acids, folate, and the human bacterial microbiome.


Autism spectrum disorder B12 Brain-derived neurotrophic factor Cobalamin Dysbiosis Methylation Methylmalonic acid Propionic acid Micronucleated lymphocytes Polyunsaturated fatty acid Short-chain fatty acids Small bowel bacterial overgrowth 

List of Abbreviations


Arachidonic acid


Attention deficit hyperactivity disorder


Autism spectrum disorder; B12 = cobalamin


Brain-derived neurotrophic factor


Docosahexaenoic acid


Eicosapentaenoic acid


Intrinsic factor


Methylmalonyl-CoA mutase




Methionine synthase


Methylmalonic acid


Micronucleated lymphocytes MTHF = methyltetrahydrofolate


Propionic acid


Polyunsaturated fatty acid






Short-chain fatty acids


Small bowel bacterial overgrowth




Vitamin B12 (cobalamin) is essential and cannot be synthesized by humans. Cobalamin refers to a corrin ring-containing cobalt complex belonging to a larger group of cobalamin corrinoids (Krautler 2012). The richest dietary cobalamin sources include red meat, liver, and organ meat (Gille and Schmid 2015; Williams 2007). In industrialized countries, red and organ meat intake has declined amid increasing vegetarian and vegan trends (Clonan et al. 2016; Daniel et al. 2011). Generally then, there has been an overall decline in cobalamin intakes among industrialized populations, which can have negative multigenerational impacts. Low cobalamin status increases neural tube risk (Molloy et al. 2009). Cobalamin deficiency is associated with a higher rate of miscarriages (Bennett 2001). Breastfed babies of vegan or vegetarian mothers can exhibit profound neurological delays and evidence of under-myelination on MRI (Lovblad et al. 1997; Kocaoglu et al. 2014; Guez et al. 2012).

Cobalamin is a component of key enzymes that influence both the homocysteine-methionine pathway and the propionic-succinic acid pathway, potentially altering DNA and cellular energy production. Equally, propionic acid-producing small bowel intestinal bacteria can modify cobalamin absorption and host cobalamin availability as well as influence fatty acid-mediated inflammatory responses and brain fatty acids. Cobalamin, therefore, demonstrates a unique interplay with the gut microbiome, with methylation cofactors, and with short-chain (propionic acid) and polyunsaturated fatty acids (PUFA) in an epigenetic manner.

Cobalamin Absorption and Metabolism: Interrelationships with Gut Microbiota and PPA

Once cobalamin is consumed in the diet, it must undergo a complex process of absorption (Fig. 1), including hydrochloric acid-mediated isolation from protein in the stomach, bonding with parietal cell-secreted haptocorrin-binding proteins and intrinsic factor in the duodenum, receptor-mediated absorption of the intrinsic factor (IF)-cobalamin complex in the terminal ileum, and transformation via the binding protein transcobalamin into the biologically active holotranscobalamin which is delivered through the blood to all the cells in the body (Schjonsby 1989).
Fig. 1

B12 digestion and metabolism with associated pathway modifying factors. B12 cobalamin, HC1 hydrochloric acid, IF intrinsic factor, IF-B12 intrinsic factor-bound B12, R-protein haptocorrin, R-B12 R-protein-bound B12

Only 1% of cobalamin intake can be passively absorbed; 99% must be IF facilitated, and IF is produced by the gastric parietal cells (Muyshondt and Schwartz 1964). Thus gastrointestinal (GI) health can have a profound effect on the bioavailability and absorption of dietary cobalamin intakes. At the first juncture, insufficiency of gastric acid can alter the ability to cleave cobalamin from dietary protein. Gastric hypochlorhydria can reduce parietal cell secretions (McKoll et al. 1998) and contribute to atrophic gastritis (Sipponen et al. 1996) and small bowel bacterial overgrowth (SIBO) (Belitsos et al. 1992). Paradoxically, hypochlorhydria can lead to heartburn and high acid symptoms (Bredenoord et al. 2006). Treatment for heartburn symptoms includes acid-reducing medications such as proton pump inhibitors and H2 antagonists. Use of acid-reducing medication is associated with cobalamin deficiency and increased methylmalonic acid (MMA) (Ruscin et al. 2002; Saltzman et al. 1994). Proton pump inhibitor (PPI) use is also associated with SIBO (Fujimori 2015; Lewis et al. 1996); in one study, 53% of patients on omeprazole demonstrated SIBO (Thorens et al. 1996). Acid-reducing medications are increasingly prescribed to pregnant women, children, and infants (Diav-Citrin et al. 2005; Smith et al. 2013; Van der Pol et al. 2011) and may have a multigenerational impact on the human microbiome.

At the next juncture in cobalamin digestion, alterations in GI epithelial health can influence the ability to produce and release IF, a rate-limiting step in absorption. The incidence of atrophic gastritis, celiac disease, non-gluten enteropathies, and inflammatory bowel disease is rising in industrialized countries. Gastritis is associated with villous atrophy, impaired IF production, and compromised cobalamin absorption (Lebwohl et al. 2015; Meyniel et al. 1981; Wood et al. 1964). SIBO is associated with villous atrophy (Lappinga et al. 2010) and may be reversible with antibiotic treatments (Haboubi et al. 1991). Patients with atrophic gastritis and bacterial overgrowth absorb significantly less protein-bound cobalamin, which is reversed by antibiotics (Suter et al. 1991).

At the third juncture of cobalamin absorption, exocrine pancreatic insufficiency may preferentially transfer the cobalamin to alternative proteins than IF, rendering the cobalamin functionally inaccessible to the human host (Marcoullis et al. 1980). Pancreatic insufficiency can also contribute to the development of SIBO (Therrien et al. 2016).

Thus, there is considerable overlap between conditions contributing to cobalamin malabsorption and to SIBO. Further, once established, large colonies of small bowel bacteria may have unique needs for cobalamin. Although some bacterial species can produce their own cobalamin (Morita et al. 2008; LeBlanc et al. 2013), excessive bacterial growth may set up an environment of competition for cobalamin between bacterial residents and the human host (Brandt et al. 1977; Degnan et al. 2014; Schjonsby, 1989). Some small bowel bacteria can selectively couple dietary cobalamin to alternative binding proteins, forming non-IF complexes which are inaccessible to the human host and deprive the host of this essential cobalamin source. At the same time, small bowel bacteria may themselves produce cobalamin corrinoids whose molecular structure does not allow them to be used by humans (Schjonsby 1989). A decrease in IF-bound cobalamin availability to the human host amid extensive bacterial production of human-inaccessible corrinoid forms may not only contribute to cobalamin deficiency development but also mask the diagnosis of cobalamin deficiency if only serum cobalamin is tested. Serum cobalamin measures only total corrinoids and is not able to distinguish between human-specific and bacteria-specific cobalamin corrinoids (Degnan et al. 2014). Overgrowth of small bowel bacteria may therefore contribute to a deceivingly normal or even elevated total cobalamin corrinoid status while obscuring human-specific cobalamin deficiency.

Small bowel bacterial overgrowth is associated with increased bacterial production of short-chain fatty acids (SCFA) such as butyrate, propionate, and acetate. Although these SCFA s may be largely anti-inflammatory at normal physiological levels (Rios-Covian et al. 2016), excess production of propionic acid (PPA) may have negative implications in SIBO, particularly in association with the neurodevelopmental disorder of autism spectrum disorder (ASD) (Frye et al. 2015). Elevated concentrations of several propionate-producing bacterial species have been isolated in stool samples of children with ASD, as have elevated levels of PPA (Finegold et al. 2010; Song et al. 2004; Wang et al. 2012). Though genetically mediated propionic acidemia does not usually elicit symptoms of ASD, cerebral infusions of PPA in the rodent model do (Al-Owain et al. 2013; McFabe et al. 2007). A multifactorial association between elevated PPA levels and the complex symptomology of autism has been evocatively formulated by McFabe et al. Pediatric antibiotic treatment and high intakes of carbohydrates and PPA additive-rich foods have been identified as possible contributing causes to both small bowel bacteria overgrowth and elevated PPA concentrations in ASD (McFabe 2012).

In humans, propionic acid is a first-step product of cholesterol, odd-chain fatty acid, and select amino acid metabolism along the succinic acid pathway (Fig. 2), leading into the Krebs energy cycle. It is of note that methionine, one of the amino acid precursors for PPA production, is an end product of the cobalamin-dependent homocysteine methylation cycle via the cobalamin-dependent enzyme methionine synthase (MetH). In the second step, the propionyl-CoA is converted to methylmalonyl-CoA via the biotin-dependent enzyme propionyl carboxylase, followed by conversion to succinyl-CoA via the cobalamin-dependent enzyme methylmalonyl-CoA mutase (MCM) (Takahashi-Iniguez et al. 2012).
Fig. 2

Bidirectional propionic-succinic acid pathway. Bacterial reconversion of methylmalonyl-CoA to propionyl-CoA may mask potential methylmalonic acidemia of B12 deficiency. B12 cobalamin, CoA coenzyme A

Thus, human-accessible cobalamin corrinoids are critically implicated in both the production and degradation of propionic acid. Methionine synthase and methylmalonyl-CoA mutase are the only two cobalamin-dependent enzymes in human metabolism. However, within the bacterial microbiome of the human gut, there are many cobalamin corrinoid-dependent enzymes, among which MCM and MetH are the most prominent (Degnan et al. 2014). In some bacteria, the conversion of PPA to succinic acid via cobalamin-specific MMA can also be a particularly useful bidirectional pathway (Fig. 2); anaerobic bacteroides can capitalize on the production of CO2 from the decarboxylation of MMA by running the pathway in reverse, thereby also increasing the pool of PPA (Fischbach and Sonnenburg 2011).

Cobalamin and PPA in Autism: Interrelationships with MMA and the Microbiome

Much recent attention has been given to a potential association between small bowel dysbiosis and elevated propionic acid in the pathophysiology of autism. However, the production of PPA as part of a cobalamin-dependent continuum involving MMA must also be taken into account, especially given the interrelatedness of human cobalamin species with the pathway substrates, products, and essential enzyme activities. MMA is emerging as an important metabolite biomarker of functional cobalamin deficiency since the bioactive corrinoid adenosylcobalamin is a rate-limiting ingredient in the MMA conversion to succinic acid. Thus, in many conditions, MMA levels may rise before serum cobalamin levels drop (Klee 2000). It is also of note that in cobalamin-deficient patients, antibiotic treatment can lower MMA levels without altering homocysteine levels, indicating that PPA produced by anaerobic gut bacteria may be a precursor to MMA in cobalamin-deficient patients (Lindenbaum et al. 1990). Equally, however, early work on organic acidemias raised the question of whether the presence of excess PPA could mask a concurrent elevation in MMA (Duran et al. 1973). Bacteria can produce PPA from non-SCFA precursors moving forward along the PPA to succinic acid pathway. However, anaerobic bacteria are also able to produce PPA from MMA moving backward along the PPA to succinic acid pathway, in order to increase CO2 production (Fischbach and Sonnenburg 2011). This latter cobalamin-independent conversion of MMA to PPA, such as in established small intestinal bacterial overgrowth (SIBO), could conceivably reduce the hallmark elevations of MMA which are diagnostically important to the confirmation of cobalamin deficiency and, at the same time, contribute to the elevations in PPA theoretically linked to the pathophysiology of autism.

Symptoms of cobalamin deficiency resemble those of autism (Agrawal and Nathani 2009), and levels of methylcobalamin, adenosylcobalamin, and methionine are lower in the autistic brain (Zhang et al. 2016). Symptoms associated with PPA administration to rats also resemble autism (McFabe 2012). However, documentation of PPA and MMA levels in human autism research is limited. One study of 58 children with autism found unexpectedly lower stool PPA than among controls (Adams et al. 2011a), while stool PPA was significantly elevated among a group of 23 children with autism compared to controls (Wang et al. 2012). In a retracted Lancet study (Wakefield et al. 1998), urinary MMA levels were elevated among 8 children with autism and GI symptomology. By contrast, no significant elevations in plasma MMA were found among a group of 55 children with ASD; however, there were also no indications of significant GI symptomology or SIBO among this group (Adams et al. 2011b). In a case report of a young child with ASD and evidence of small bowel bacterial overgrowth, there was a high-normal MMA which was nonresponsive to oral cobalamin intervention (Fitzgerald et al. 2012). However, when subcutaneous cobalamin injections were initiated, bypassing the SIBO issue, there were dramatic improvements in behavior and development. Thus, children with autism and concurrent significant GI symptoms may have higher MMA levels than children with autism and minimal GI symptoms, potentially confirming that SIBO could contribute to elevated MMA levels. Further, in SIBO, bacteria may preferentially sequester supplemental cobalamin travelling through the GI tract and limit the effectiveness of oral cobalamin treatment. The reportedly dramatic impact of subcutaneous cobalamin treatment on behavior and development in an ASD child previously nonresponsive to oral supplementation would appear to confirm the preferential sequestering of oral cobalamin by small bowel bacteria and the need to bypass the gut for effective redress of functional cobalamin deficiency during SIBO.

Cobalamin and Epigenetics: Interrelationships with Folate and Gut Microbiota

Alterations in human-accessible cobalamin availability in conditions of small bowel bacterial overgrowth will have effects on other biochemical pathways, with potential epigenetic implications. Notably, the methylation of homocysteine to methionine is both cobalamin and folate dependent and directly impacts DNA synthesis. If there is insufficient cobalamin, or if the cobalamin is oxidized during oxidative stress, methyltetrahydrofolate (MTHF) will not be converted to tetrahydrofolate (THF) for recycling, and methionine synthase production (MetH) will drop with reduced conversion of homocysteine to methionine. This reduction in methionine synthesis will then impact the methylation of DNA via the S-adenosylmethionine (SAM-e) to S-adenosylhomocysteine (SAH) pathway (Chiang et al. 1996; Waterland). Changes in DNA methylation are principal epigenetic mediators. Rodent experiments supplementing methylation cofactors before and during pregnancy have demonstrated increased DNA methylation in both early and mid-gestation (Waterland 2006; Waterland et al. 2006). The increased DNA methylation in response to gestational supplementation does not appear to be multigenerational in nature (Waterland et al. 2007).

Targeted cobalamin and folate supplementation in humans has also been shown to alter DNA, as determined by the frequency of micronucleated lymphocytes (MNL) . In both adolescent and adult males, the frequency of MNL demonstrated a significant negative relationship with serum cobalamin levels but not folate status, despite the absence of clinical cobalamin deficiency. Although the adolescents were each supplemented with 3.5 and 10 times the RDI for both folate and cobalamin, the magnitude of serum cobalamin increase was much smaller than that of the RBC folate increase. Further, the increases in folate status were not associated with the improvements in MNL frequency seen with improved cobalamin status. Overall, the greatest reduction in MNL frequency was achieved at post-supplementation cobalamin levels >300 pmol/L (Fenech et al. 1997, 1998). The differences in cobalamin and folate response to supplementation may reflect differences in barriers to absorption between dietary folate and cobalamin and underline the challenges in addressing the epigenetic consequences of cobalamin deficiency through gut-mediated fortification or supplementation.

Children with Down syndrome exhibit altered cobalamin- and folate-mediated homocysteine-to-methionine conversion, and a higher frequency of MNL , than do controls (Youness et al. 2016). Levels of micronucleated lymphocytes are also elevated among young mothers of children with Down syndrome, which may indicate a multigenerational effect (Coppede et al. 2016). Children with autism who also have altered homocysteine-methionine function may or may not have similar increased rates of micronucleated cells: among a small number of sibling pairs (6), indicators of DNA damage (including micronuclei frequency) in response to hydrogen peroxide challenge were higher among the children with autism, but failed to reach statistical significance. However, the children with autism did demonstrate higher rates of lymphoblast necrosis (Main et al. 2013).

In theory, this altered homocysteine-to-methionine conversion associated with cobalamin deficiency should result in increased homocysteine levels and provide a potentially useful diagnostic index of cobalamin status. However, homocysteine is not always elevated in cobalamin deficiency (Fig. 3); in some cases, extra homocysteine is diverted into the transsulfuration pathway to produce cysteine and glutathione (Stipanuk and Ueki 2011). In other cases, betaine (trimethylglycine) may upregulate the homocysteine-methionine pathway via betaine homocysteine methyltransferase (BHMT) and bypass limitations imposed by reduced cobalamin-dependent methionine synthase activity (Kim and Kim 2005).
Fig. 3

Homocysteine metabolism and B12-independent pathways. B12 cobalamin, BHMT betaine homocysteine methyl transferase, CBS cystathionine beta synthase, DMG dimethylglycine, m methyl group (CH3), MS methionine synthase, MTHF methyltetrahydrofolate, THF tetrahydrofolate, TMG trimethylglycine

There is a unique dance between cobalamin and folate availability (which impacts methylation reactions throughout the human body) and their related epigenetic effects. While some human gut bacteria can produce cobalamins which are inaccessible to the human host, other flora can synthesize folates which appear to be accessible to the host (Leblanc et al. 2013; Rossi et al. 2011). Rat studies have identified significantly higher fecal folate levels among Bifidobacterium models which correlate with serum folate levels and hemoglobin and mean cell volume status (Sugahara et al. 2015). The balance between bacteria variants in the gut may thus influence the balance between cobalamin and folate in human.

On a larger scale, relative ratios between dietary intakes of cobalamin and folate may also influence methylation pathways and DNA methylation. Since the late 1990s, numerous countries have elected to add synthetic folic acid to flour to reduce neural tube defects and to encourage the use of synthetic folic acid-containing supplements, particularly among women who are pregnant or of child-bearing age. Levels of total RBC folate and unmetabolized folic acid are elevated in the populations of several folate-fortified nations. Unmetabolized folic acid has also been detected in the cord blood of infants whose mothers did not receive maternal folate supplements (Obeid et al. 2010). By contrast, serum cobalamin levels are not elevated (McFarlane et al. 2011). Among Canadian women, cobalamin levels were lowest among adolescents and women of child-bearing age; lower cobalamin status was associated with higher homocysteine levels (McFarlane et al. 2011).

The biological significance of supraphysiological total folate and high levels of unmetabolized folate, particularly in the context of cobalamin- and folate-related polymorphisms, remains to be clarified. Supraphysiological folate may mask the macrocytic anemia of cobalamin deficiency, further complicating a complicated diagnosis (Wyckoff and Ganji 2007). There may also be subpopulations who are more sensitive than others to the accumulation of synthetic folate, as evidenced by differences between Canadian women with and without detectable unmetabolized folic acid levels following supplementation (Tam et al. 2012). However, an elevated ratio of folate to cobalamin has been associated with adverse neurological effects among the elderly (Morris et al. 2007) and with altered hippocampal microstructure and memory performance (Kobe et al. 2016) in adults. An increased folate-to-cobalamin ratio is also associated with embryonic delay and growth retardation in mice (Pickell et al. 2011) and with reduced neonatal growth anthropometrics in humans (Gadgil et al. 2014). Intake of synthetic folic acid supplements during pregnancy has been positively correlated with risk of autism in analyses of the Rochester (MN) Epidemiology Project and the Centers for Disease Control and Prevention pediatric dataset, respectively (Beard et al. 2011; DeSoto et al. 2012). High folate in the presence of genetic alterations to folate/homocysteine pathways may also increase the risk of Down syndrome (Coppede 2009).

Cobalamin and Brain Function: Interrelationships with PUFA, Microbiota, and PPA

The ratio of cobalamin to folate may also interact with the composition of polyunsaturated fatty acids, which are important methyl group acceptors, in the brain. Among older persons with mild cognitive impairment, cobalamin and folic acid supplementation appears to slow the rate of brain atrophy among patients with high baseline omega-3 fatty acids. However, there was no benefit from folate and cobalamin supplements among patients with lower omega-3 levels (Jerneren et al. 2015). The ratio of folic acid to cobalamin during pregnancy can have direct impacts on fetal brain docosahexaenoic acid (DHA) and arachidonic acid (AA) accretion. During pregnancy, maternal DHA levels are primary regulators of brain DHA in offspring, while fetal DHA status influences neurogenesis and neuron survival during pregnancy (Dhobale and Joshi 2012). However, in rat studies, excess folate supplementation of cobalamin-deficient mothers decreased DHA concentrations in both mothers and offspring. Omega-3 supplementation of cobalamin-deficient rats receiving high folate improved DHA levels in both mother and offspring, but AA levels were reduced. Rates of malondialdehyde (MDA), indicative of lipid peroxidation, were also elevated in B12-deficient rats and offspring receiving high folate (Roy et al. 2012). Further study identified alterations in the mRNA of brain-derived neurotrophic factors (BDNF) in offspring of rats fed with high-folate, cobalamin-deficient diets; in rats receiving prenatal supplements of DHA and eicosapentaenoic acid (EPA), abnormal mRNA of BDNF was normalized (Sable et al. 2014).

DHA levels are lower in children with autism (Brigandi et al. 2015) and attention deficit hyperactivity disorder (ADHD) (Parletta et al. 2016). DHA supplementation of children with autism failed to demonstrate significant positive effects in core behavioral symptoms (Voigt et al. 2014). However, interactions between DHA and methylation nutrients such as folate and cobalamin were not accounted for. It is possible that correction of potential folate-to-cobalamin imbalances may be required before a therapeutic response to DHA supplementation can be demonstrated in autism. Similar limitations to study protocols and therapeutic outcomes are evident in omega-3 supplementation research with ADHD (Gillies et al. 2012).

Gut microbiota can alter the impact of omega-3 and omega-6 fatty acid ratios in mice in vivo, and vice versa (Kaliannan et al. 2015; Wall et al. 2009). Mice fed an omega-6-enriched diet demonstrate elevated levels of gastrointestinal inflammatory biomarkers; this effect is not seen in genetically altered mice that intrinsically produce omega-3 fatty acids. Treatment with antibiotics eliminates the effect. Microbiome analyses indicate omega-3-producing mice have higher counts of anti-inflammatory bacterial species including bifidobacterium and lactobacillus strains; mice with high omega-6 and inflammatory biomarker levels demonstrate bacterial overgrowth with pro-inflammatory proteobacteria. Cohousing of the mouse types leads to fecal transfer of bacteria from the omega-3 mice, which increased intestinal zinc-dependent alkaline phosphatase levels and altered bacterial growth in the omega-6 mice toward anti-inflammatory species (Kaliannan et al. 2015).

In humans, fish oil supplementation in combination with breastfeeding cessation altered the gut bacterial species of infants, compared to sunflower oil supplements (Andersen et al. 2011). Among older adults, a high omega-6 diet altered gut flora and caused gut dysbiosis ; this effect was reversed by fish oil supplementation (Ghosh et al. 2013). A further mouse study found that in utero and early life omega-3 supplementation beneficially altered not only gut microbiota but also depressive, social, and cognitive behaviors during later life (Robertson et al. 2016); however, some of the effects of DHA supplementation, and the subsequently altered gastric microbiome, appear to be gender specific and stronger among males (Davis et al. 2017). Rates of autism spectrum disorder and ADHD are also higher among males (CDC).

Administration of gut dysbiosis-related PPA (Fig. 4) to rats decreased absolute levels of omega-3 fatty acids, AA, and fatty acid ratios, as well as induced autistic behaviors (El-Ansary and Al-Ayadhi 2014). However, omega-3 fatty acid supplementation conferred protection against the neurotoxic effects of PPA administration, suggesting the potential to modify the symptoms of the PPA-induced autism and gut dysbiosis model (El-Ansary et al. 2011). Like PPA administration, cobalamin deficiency also decreased DHA levels in the rat model and was associated with symptoms of autism (Kulkarni et al. 2011). However, maternal cobalamin supplementation alone increased DHA levels, BDNF , and cognition in rat offspring, thereby demonstrating power to modify brain fatty acids and neurodevelopment even in the absence of preexisting cobalamin deficiency. This effect was amplified by concomitant omega-3 supplementation (Rathod et al. 2014) and by multigenerational supplementation (Rathod et al. 2016), suggesting an important potential epigenetic impact of cobalamin supplementation on gut dysbiosis-mediated alterations in brain development and function.
Fig. 4

Overlapping epigenetic impacts of PPA and B12 on brain DHA and symptoms of autism. B12 cobalamin, DHA docosahexaenoic acid, PPA propionic acid


Gut microbiota (Fig. 5) can influence fatty acid composition which, in turn, can alter gut microbiota. Elevated PPA is associated with gut dysbiosis, and gut dysbiosis is associated with altered cobalamin bioavailability. Both PPA administration and cobalamin deficiency can decrease essential fatty acid levels and cause symptoms of autism. Cobalamin supplementation can raise DHA levels and improve autistic symptoms, while omega-3 supplementation can improve the symptoms of PPA administration. If the neurotoxic effects of PPA associated with gut dysbiosis can be reversed by omega-3 supplementation, and if cobalamin supplementation can raise levels of brain omega-3 and neurotrophic growth factor, it is possible that the pathologies of cobalamin deficiency and PPA neurotoxicity are intricately interrelated with each other, with polyunsaturated fatty acids and with the gut microbiome in a strongly epigenetic manner. Within this theoretical framework, stepwise alterations of cobalamin, folate, and essential fatty acid levels in a PPA-gut dysbiosis model may be able to modify gut microbiota, PPA production, core methylation pathways, as well as brain fatty acid distributions, myelination patterns, and DNA integrity.
Fig. 5

Unifying hypothesis of cobalamin and microbiota in epigenetics. B12 cobalamin, BDNF brain-derived neurotrophic factors, DHA docosahexaenoic acid, N-3 PUFA omega-3 polyunsaturated fatty acids, PPA propionic acid

Dictionary of Terms

  • Autism – a pediatric neurological disorder affecting communication, behavior, and cognition.

  • Cobalamin – a cobalt-based vitamin and essential enzymatic cofactor for pathways affecting DNA and RNA.

  • Gut dysbiosis – bacterial imbalance causing inflammation and nutrient malabsorption.

  • Polyunsaturated fatty acids – double-bond fatty acids important for brain function including DHA, EPA, and AA.

  • Propionic acid – a short-chain fatty acid produced by bacteria, fermentation, and metabolism of some amino and fatty acids.

Key Facts About Vitamin Cobalamin

  • Cobalamin supports normal production of white blood cells and platelets, affecting immune responses and blood clotting.

  • Cobalamin assists in red blood cell and hemoglobin production to carry oxygen to tissues and organs.

  • Cobalamin assists in myelin formation, the insulating sheath that protects nerves throughout the brain and body.

  • Cobalamin influences production of neurotransmitters such as dopamine and serotonin.

  • Cobalamin influences hormonal regulation of bone growth and strength.

Summary Points

  • Some bacteria compete for cobalamin, divert human-accessible cobalamin into human-inaccessible forms, and alter the gut environment, influencing cobalamin absorption, bioavailability, metabolism, and assessment.

  • Cobalamin deficiency can raise methylmalonic acid (MMA) and alter the propionic → methylmalonic → succinic acid pathway.

  • Small bowel bacterial overgrowth can increase propionic acid (PPA) from precursors; some bacteria reverse MMA to PPA, increasing total PPA.

  • Both cobalamin deficiency and PPA can cause autistic symptoms and alter brain function.

  • Cobalamin-folate ratios modify PPA and MMA production, alter methylation pathways and DNA, and impact pregnancy outcomes and brain function.

  • Cobalamin-folate ratios alter brain polyunsaturated fatty acid (PUFA) levels and response to PUFA supplementation.

  • Gut bacteria alter PUFA levels; PUFA supplementation can alter gut bacterial species.

  • Both cobalamin deficiency and PPA administration can alter brain PUFA levels, and altered brain PUFA levels are associated with autism.

  • PUFA supplementation can reverse the neurotoxicity of PPA.

  • Cobalamin supplementation can raise PUFA levels.

  • Cobalamin and PUFA supplementation, with controlled cobalamin-folate ratios, may epigenetically modify the PPA model of autism.


  1. Adams JB, Johansen LJ, Powell LD et al (2011a) Gastrointestinal flora and gastrointestinal status in children with autism – comparisons to typical children and correlation with autism severity. BMC Gastroenterol 11:22CrossRefPubMedPubMedCentralGoogle Scholar
  2. Adams JB, Audhya T, McDonough-Means S et al (2011b) Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (London) 8(34):1–32Google Scholar
  3. Agrawal S, Nathani S (2009) Neuro-regression in vitamin B12 deficiency. BMJ Cas Rep 2009:bcr06.2008.0235Google Scholar
  4. Al-Owain M, Kaya N, Al-Shamrani H et al (2013) Autism spectrum disorder in a child with propionic acidemia. JIMD Rep 7:63–66CrossRefPubMedGoogle Scholar
  5. Andersen AD, Molbak L, Michaelsen KF et al (2011) Molecular fingerprints of the human fecal microbiota from 9 to 18 months old and the effect of fish oil supplementation. J Pediatr Gastroenterol Nutr 53(3):303–309CrossRefPubMedGoogle Scholar
  6. Beard CM, Panser LA, Katusic SKI (2011) Folic acid supplementation a risk for autism? Med Hypoth 77(1):15–17CrossRefGoogle Scholar
  7. Belitsos PC, Greenson JK, Yardley JH et al (1992) Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. J Infect Dis 166(2):277–284CrossRefPubMedGoogle Scholar
  8. Bennett M (2001) Vitamin B12 deficiency, infertility and fetal loss. J Reprod Med 46(3):209–212PubMedGoogle Scholar
  9. Brandt LJ, Berstein LH, Wagle A (1977) Production of vitamin B12 analogues in patients with small-bowel bacterial overgrowth. Ann Intern Med 87(5):546–551CrossRefPubMedGoogle Scholar
  10. Bredenoord AJ, Baron A, Smout AJPM (2006) Symptomatic gastro-oesophageal reflux in a patient with achlorhydria. Gut 55(7):1054–1055CrossRefPubMedPubMedCentralGoogle Scholar
  11. Brigandi SA, Shao H, Qian SY et al (2015) Autistic children exhibit decreased levels of essential fatty acids in red blood cells. Int J Mol Sci 16(5):10061–10076CrossRefPubMedPubMedCentralGoogle Scholar
  12. Chiang PK, Gordon RK, Tal J et al (1996) S-Adenosylmethionine and methylation. FASEB J 10:471–480PubMedGoogle Scholar
  13. Clonan A, Roberts KE, Holdsworth M (2016) Socioeconomic and demographic drivers of red and processed meat consumption: implications for health and environmental sustainability. Proc Nutr Soc 75(3):367–373CrossRefPubMedPubMedCentralGoogle Scholar
  14. Coppede F (2009) The complex relationship between folate/homocysteine metabolism and risk of down Syndrome. Mutat Res 682(1):54–70CrossRefPubMedGoogle Scholar
  15. Coppede F, Denaro M, Tannorella P, Migliore L (2016) Increased MTHFR promotor methylation in young mothers of down Syndrome individuals. Mutat Res 787:1–6CrossRefPubMedGoogle Scholar
  16. Daniel CR, Cross AJ, Koebnick C et al (2011) Trends in meat consumption in the United States. Public Health Nutr 14(4):575–583CrossRefPubMedGoogle Scholar
  17. Davis DJ, Hecht PM, Jasarevic E et al (2017) Sex-specific effects of docosahexaenoic acid (DHA) on the microbiome and behaviour of socially-isolated mice. Brain Behav Immun 59:38–48CrossRefPubMedGoogle Scholar
  18. Degnan PH, Taga ME, Goodman AL (2014) Vitamin B12 as a modulator of gut microbial ecology. Cell Metab 20(5):769–778CrossRefPubMedPubMedCentralGoogle Scholar
  19. DeSoto MC, Hitlan RT (2012) Synthetic folic acid supplementation during pregnancy may increase risk of developing autism. J Ped Biochemist 2(4):251–261Google Scholar
  20. Dhobale M, Joshi S (2012) Altered maternal micronutrients (folic acid, vitamin B12) and omega 3 fatty acids through oxidative stress may reduce neurotrophic factors in preterm pregnancy. J Matern Fetal Neonatal Med 25(4):317–325CrossRefPubMedGoogle Scholar
  21. Diav-Citrin O, Arnon J, Schectman S (2005) The safety of proton pump inhibitors in pregnancy: a multicenter prospective controlled study. Aliment Pharmacol Ther 21(3):269–275CrossRefPubMedGoogle Scholar
  22. Duran M, Ketting D, Wadman SK et al (1973) Propionic acid, an artifact which can leave methylmalonic acidemia undiscovered. Clinica Chemica Acta 49:177–179CrossRefGoogle Scholar
  23. El-Ansary A, Al-Ayadhi L (2014) Relative abundance of short chain and polyunsaturated fatty acids in propionic acid-induced autistic features in rat pups as potential markers in autism. Lipids Health Dis 13:140CrossRefPubMedPubMedCentralGoogle Scholar
  24. El-Ansary AK, Al-Daihan SK, El-Gezeery AR (2011) On the protective effect of omega-3 against propionic acid-induced neurotoxicity in rat pups. Lipids Health Dis 10:142CrossRefPubMedPubMedCentralGoogle Scholar
  25. Fenech MF, Dreosti IE, Rinaldi JR (1997) Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis 18(7):1329–1336CrossRefPubMedGoogle Scholar
  26. Fenech M, Aitken C, Rinaldi J (1998) Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis 19(7):1163–1171CrossRefPubMedGoogle Scholar
  27. Finegold SM, Dowd SE, Gontcharova V et al (2010) Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16(4):444–453CrossRefPubMedGoogle Scholar
  28. Fischbach MA, Sonnenburg JL (2011) Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe 10(4):336–347CrossRefPubMedPubMedCentralGoogle Scholar
  29. Fitzgerald K, Hyman M, Swift K (2012) Autism Spectrum disorders. Glob Adv Health Med 1(4):62–74CrossRefPubMedPubMedCentralGoogle Scholar
  30. Frye RE, Rose S, Slattery J et al (2015) Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome. Microb Ecol Health Dis 26:2748Google Scholar
  31. Fujimori S (2015) What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 21(22):6817–6819CrossRefPubMedPubMedCentralGoogle Scholar
  32. Gadgil M, Joshi K, Pandit A et al (2014) Imbalance of folic acid and vitamin B12 is associated with birth outcome: an Indian pregnant women study. Eur J Clin Nutr 68(6):726–729CrossRefPubMedGoogle Scholar
  33. Ghosh S, Molcan E, DeCoffe D et al (2013) Diets rich in n-6 PUFA induce intestinal microbial dysbiosis in aged mice. Brit J Nutr 110(3):515–523CrossRefPubMedGoogle Scholar
  34. Gille D, Schmid A (2015) Vitamin B12 in meat and dairy products. Nutr Rev 73(2):106–115CrossRefPubMedGoogle Scholar
  35. Gillies D, Sinn JK, Lad SS et al (2012) Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 7:CD007986Google Scholar
  36. Guez S, Chiarelli G, Menni F et al (2012) Severe vitamin B12 deficiency in an exclusively breastfed 5-month-old Italian infant born to a mother receiving multivitamin supplementation during pregnancy. BMC Pediatr 12:85CrossRefPubMedPubMedCentralGoogle Scholar
  37. Haboubi NY, Lee GS, Montgomery RD (1991) Duodenal mucosal morphometry of elderly patients with small intestinal bacterial overgrowth: response to antibiotic treatment. Age Ageing 20(1):29–32CrossRefPubMedGoogle Scholar
  38. Jerneren F, Elshorbagy AK, Oulhaj A (2015) Brain atrophy in cognitively impaired elderly: the importance of long-chain w-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr 102(1):215–221CrossRefPubMedGoogle Scholar
  39. Kaliannan K, Wang B, Li X-Y et al (2015) A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on endotoxemia. Sci Rep 5:11276CrossRefPubMedPubMedCentralGoogle Scholar
  40. Kim SK, Kim YC (2005) Effects of betaine supplementation on hepatic metabolism of sulphur-containing amino acids in mice. J Hepatol 42(6):907–913CrossRefPubMedGoogle Scholar
  41. Klee GG (2000) Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem 46(8):1277–1283PubMedGoogle Scholar
  42. Kobe T, Witte AV, Schnelle A et al (2016) Vitamin B-12 concentration, memory performance, and hippocampal structure in patients with mild cognitive impairment. Am J Clin Nutr 103(4):1045–1054CrossRefPubMedGoogle Scholar
  43. Kocaoglu C, Akin F, Caksen H et al (2014) Cerebral atrophy in a vitamin B12-deficient infant of a vegetarian mother. J Health Popul Nutr 32(2):367–371PubMedPubMedCentralGoogle Scholar
  44. Krautler B (2012) Biochemistry of B12-cofactors in human metabolism. Subcell Biochem 56:323–346CrossRefPubMedGoogle Scholar
  45. Kulkarni A, Dangat K, Kale A et al (2011) Effects of altered maternal folic acid, vitamin B12 and docosahexaenoic acid on placental global DNA methylation patterns in Wistar rats. PLoS One 6(3):e17706CrossRefPubMedPubMedCentralGoogle Scholar
  46. Lappinga PJ, Abraham SC, Murray JA et al (2010) Small intestinal bacterial growth: histopathological features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 134(2):264–270PubMedGoogle Scholar
  47. LeBlanc JG, Milani C, de Giori GS et al (2013) Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 24(2):160–168CrossRefPubMedGoogle Scholar
  48. Lebwohl B, Green PH, Genta RM (2015) The coeliac stomach: gastritis in patients with coeliac disease. Alimen Pharmaco Ther 42(2):180–187CrossRefGoogle Scholar
  49. Lewis SJ, Franco S, Young G et al (1996) Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 10(4):557–561Google Scholar
  50. Lindenbaum J, Savage DG, Stabler SP et al (1990) Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 34:99–107CrossRefPubMedGoogle Scholar
  51. Lovblad K, Ramelli G, Remonda L et al (1997) Retardation of myelination due to dietary B12 deficiency: cranial MRI findings. Pediatr Radiol 27(2):155–158CrossRefPubMedGoogle Scholar
  52. MacFabe DF (2012) Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis 23:1–24Google Scholar
  53. MacFabe DF, Cain DP, Rodriguez-Capote K et al (2007) Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res 176(1):149–169CrossRefPubMedGoogle Scholar
  54. MacFarlane AJ, Greene-Finestone LS, Shi Y (2011) Vitamin B-12 and homocysteine status in a folate-replete population: results from the Canadian health measures survey. Am J Clin Nutr 94(4):1079–1087CrossRefPubMedGoogle Scholar
  55. Main PA, Thomas P, Esterman A et al (2013) Necrosis is increased in lymphoblastoid cell lines from children with autism compared with their non-autistic siblings under conditions of oxidative and nitrosative stress. Mutagenesis 28(4):475–484CrossRefPubMedPubMedCentralGoogle Scholar
  56. Marcoullis G, Parmentier Y, Nicolas JP et al (1980) Cobalamin malabsorption due to nondegradation of R proteins in the human intestine. Inhibited cobalamin absorption in exocrine pancreatic dysfunction. J Clin Invest 66(3):430–440CrossRefPubMedPubMedCentralGoogle Scholar
  57. McKoll KE, el-Omar E, Gillen D (1998) Interactions between H. Pylori infection, gastric secretion and anti-secretory therapy. Mr Med Bull 54(1):121–138CrossRefGoogle Scholar
  58. Meyniel D, Petit J, Bodin F et al (1981) Vitamin B12 deficiency in chronic atrophic gastritis. 3 cases (author’s transl). Nouvelle Presse Med 10(27):2281–2284Google Scholar
  59. Molloy AM, Kirke PN, Troendle JF et al (2009) Maternal vitamin B12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic acid fortification. Pediatrics 123(3):917–923CrossRefPubMedPubMedCentralGoogle Scholar
  60. Morita H, Toh H, Fukuda S et al (2008) Comparative genome analysis of lactobacillus reuteri and lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production. DNA Res 15(3):151–161CrossRefPubMedPubMedCentralGoogle Scholar
  61. Morris MS, Jacques PF, Rosenberg IJ et al (2007) Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 85(1):193–2000PubMedPubMedCentralGoogle Scholar
  62. Muyshondt E, Schwartz SI (1964) Vitamin B12 absorption following vagectomy and gastric surgery. Ann Surg 160(5):788–792CrossRefPubMedPubMedCentralGoogle Scholar
  63. Obeid R, Kasoha M, Kirsch SH et al (2010) Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood. Am J Clin Nutr 92(6):1416–1422CrossRefPubMedGoogle Scholar
  64. Parletta N, Niyonsenga T, Duff J (2016) Omega-3 and omega-6 polyunsaturated fatty acid levels and correlations with symptoms in children with attention deficit hyperactivity disorder, autistic spectrum disorder and typically developing controls. PLoS One 11(5):e0156432CrossRefPubMedPubMedCentralGoogle Scholar
  65. Pickell L, Brown K, Li D et al (2011) High intakes of folic acid disrupts embryonic development in mice. Birth Defects Res A Clin Mol Teratol 91(1):8–19CrossRefPubMedGoogle Scholar
  66. Rathod R, Khaire A, Kemse N et al (2014) Maternal omega-3 fatty acid supplementation on vitamin B12 rich diet improves brain omega-3 fatty acids, neurotrophins and cognition in the Wistar rat offspring. Brain Dev 36(10):853–863CrossRefPubMedGoogle Scholar
  67. Rathod RS, Khaire AA, Aa K et al (2016) Effect of vitamin B12 and omega-3 fatty acid supplementation on brain neurotrophins and cognition in rats: a multigeneration study. Biochimie 128–129:201–208CrossRefPubMedGoogle Scholar
  68. Ríos-Covián D, Ruas-Madiedo P, Margolles A et al (2016) Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol 7:185CrossRefPubMedPubMedCentralGoogle Scholar
  69. Robertson RC, Seira Oriach C, Murphy K et al (2016) Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in adolescence and adulthood. Brain Behav Immun 59:21–37CrossRefPubMedGoogle Scholar
  70. Rossi M, Amaretti A, Raimondi S (2011) Folate production by probiotic bacteria. Forum Nutr 3(1):118–134Google Scholar
  71. Roy S, Kale A, Dangat K et al (2012) Maternal micronutrients (folic acid and vitamin B12) and omega 3 fatty acids: implications for neurodevelopmental risk in the rat offspring. Brain and Development 34(1):64–71CrossRefPubMedGoogle Scholar
  72. Ruscin JM, Page RL 2nd, Valuck RJ (2002) Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36(5):812–816CrossRefPubMedGoogle Scholar
  73. Sable P, Kale A, Joshi A et al (2014) Maternal micronutrient imbalance alters gene expression of BDNF, NGF, TrkB and CREB in the offspring at an adult age. Int J Dev Neurosci 34:24–32CrossRefPubMedGoogle Scholar
  74. Saltzman JR, Kemp JA, Golner BB et al (1994) Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr 13(6):584–591CrossRefPubMedGoogle Scholar
  75. Schjonsby H (1989) Vitamin B12 absorption and malabsorption. Gut 30:1686–1691CrossRefPubMedPubMedCentralGoogle Scholar
  76. Sipponen P, Kekki M, Seppala K et al (1996) The relationships between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther 10(1):103–118CrossRefPubMedGoogle Scholar
  77. Smith CH, Israel DM, Schreiber R et al (2013) Proton pump inhibitors for irritable infants. Can Fam Physician 59(2):153–156PubMedPubMedCentralGoogle Scholar
  78. Song Y, Liu C, Finegold SM (2004) Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol 70(11):6459–6465CrossRefPubMedPubMedCentralGoogle Scholar
  79. Stipanuk MH, Ueki I (2011) Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur. J Inherit Metab Dis 34(1):17–32CrossRefPubMedGoogle Scholar
  80. Sugahara H, Odamaki T, Hashikura N et al (2015) Differences in folate production by bifidobacteria of different origins. Biosci Microbiota Food Health 34(4):87–93CrossRefPubMedPubMedCentralGoogle Scholar
  81. Suter PM, Golner BB, Goldin BR et al (1991) Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology 101(4):1039–1045CrossRefPubMedGoogle Scholar
  82. Takahashi-Iñiguez T, García-Hernandez E, Arreguín-Espinosa R et al (2012) Role of vitamin B12 on methylmalonyl-CoA mutase activity. J Zhejiang Univ Sci B 13(6):423–437CrossRefPubMedPubMedCentralGoogle Scholar
  83. Tam C, O’Connor D, Koren G (2012) Circulating unmetabolized folic acid: relationship to folate status and effect of supplementation. Obstet Gynecol Int 2012:485179CrossRefPubMedPubMedCentralGoogle Scholar
  84. Therrien A, Bouchard S, Sidani S et al (2016) Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case-control study. Can J Gastroenterol Hepatol 2016:7424831–7424837PubMedPubMedCentralGoogle Scholar
  85. Thorens J, Froehlich F, Schwizer W et al (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective, randomized double blind study. Gut 39(1):54–59CrossRefPubMedPubMedCentralGoogle Scholar
  86. Van der Pol RJ, Smits MJ, van Wijk MP et al (2011) Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatr 127(5):925–935CrossRefGoogle Scholar
  87. Voigt RG, Mellon MW, Katusic SK et al (2014) Dietary docosahexaenoic acid supplementation in children with autism. J Pediatr Gastroenterol Nutr 58(6):715–722PubMedGoogle Scholar
  88. Wakefield AJ, Murch SH, Anthony A et al (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children (Retracted). Lancet 351(9103):637–641CrossRefPubMedGoogle Scholar
  89. Wall R, Ross RP, Shanahan F et al (2009) Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 89(5):1393–1401CrossRefPubMedGoogle Scholar
  90. Wang L, Christophersen C, Sorich M et al (2012) Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci 57(8):2096–2102CrossRefPubMedGoogle Scholar
  91. Waterland RA (2006) Assessing the effects of high methionine intake on DNA methylation. J Nutr 136(6):1706S–1710SPubMedGoogle Scholar
  92. Waterland RA, Dolinoy DC, Lin JR et al (2006) Maternal methyl supplements increase offspring DNA methylation at Axin fused. Genesis 44(9):401–406CrossRefPubMedGoogle Scholar
  93. Waterland RA, Travisano M, Tahiliani KG (2007) Diet-induced hypermethylation at agouti viable yellow is not inherited transgenerationally through the female. FASEB J 21(12):3380–3385CrossRefPubMedGoogle Scholar
  94. Williams PG (2007) Nutritional composition of red meat. Nutr Dietet 64(4):S113–S119CrossRefGoogle Scholar
  95. Wood IJ, Ralston M, Ungar B et al (1964) Vitamin B12 deficiency in chronic gastritis. Gut 5:27–37CrossRefPubMedPubMedCentralGoogle Scholar
  96. Wyckoff KF, Ganji V (2007) Proportion of individuals with low serum vitamin B-12 concentrations without macrocytosis is higher in the post folic acid fortification period than in the pre folic acid fortification period. Am J Clin Nutr 86(4):1187–1192PubMedGoogle Scholar
  97. Youness ER, Aly HF, El-Bassyouni HT et al (2016) Micronucleus assay and pro-oxidant status of patients with known chromosomal aneuploidy. Der Pharma Chemica 8(13):158–164Google Scholar
  98. Zhang Y, Hodgson NW, Trivedi MS et al (2016) Decreased brain levels of vitamin B12 in aging, autism and schizophrenia. PLoS One 11(1):e0146797CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.GuelphCanada

Personalised recommendations